This summary article contains the latest knowledge of hormonal substitution therapy at climacteric women and its impact on the potential thromboembolic risks. It thrashes out a question of haemostasis, the negative influence of some gestagenes on the glucose tolerance and the lipid metabolism.
It analyses the higher thromboembolic risks at the patients using hormonal substitution therapy. Further it quotes the results of the international studies of HRT impact on some risk factors of cardiovascular diseases.
The article emphasises the necessity of an individual choice of hormonal preparative and its form of application at any woman needing a hormonal therapy.